智翔金泰(688443.SH)2025年度归母净亏损5.36亿元

Core Viewpoint - Zhixiang Jintai (688443.SH) reported a significant increase in total operating revenue for the fiscal year 2025, while narrowing its net loss, indicating positive momentum in its business operations [1] Financial Performance - The company achieved total operating revenue of 231 million yuan, representing a year-on-year growth of 666.65% [1] - Operating profit loss narrowed by 33.57% compared to the previous year [1] - Total profit loss decreased by 32.74% year-on-year [1] - Net profit attributable to the parent company's owners showed a reduction in loss by 32.74% compared to the same period last year [1] Product Development and Market Expansion - The growth in revenue is primarily attributed to the market expansion of the company's first commercialized product, Saliqi monoclonal antibody injection (Jinlixi®), which saw steady sales growth [1] - Significant licensing income from the GR1803 injection's licensing and commercialization agreement positively impacted the company's net profit for the period [1]